Suplatast tosilate ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 226 | 間質性膀胱炎（ハンナ型） | 4 |
226. 間質性膀胱炎（ハンナ型）
臨床試験数 : 145 / 薬物数 : 156 - (DrugBank : 51) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs051210106 | 13/10/2021 | 13/10/2021 | ESTOC study | The Effect of Suplatast Tosilate for interstitial Cystitis: A randomized controlled open-label trial - ESTOC study | Interstitial cystitis bladder, inflammation, pain;D018856 | Participants will be randomly assigned to splatast group or control group. In splatast group, splatast tosilate capsule 100 mg (1 capsule at a time) will be orally administered 3 times a day between meals for 3 months. In control group, flavoxate hydrochloride tablets 200 mg (1 tablet at a time) will be orally administered 3 times a day between meals for 3 months. | Torimoto Kazumasa | Fujimoto Kiyohide | Recruiting | >= 20age old | Not applicable | Both | 100 | Phase 2 | Japan |
| 2 | EUCTR2005-003367-23-DE (EUCTR) | 13/02/2006 | 23/11/2005 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | Interstitial Cystitis / Painful Bladder Syndrome MedDRA version: 8.0;Level: LLT;Classification code 10008928 | Product Name: YM672 (IPD®) Product Code: YM672 INN or Proposed INN: Suplatast tosilate Other descriptive name: IPD® (Japanese tradename) | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Germany;Sweden | ||
| 3 | EUCTR2005-003367-23-DK (EUCTR) | 06/02/2006 | 21/12/2005 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | Interstitial Cystitis / Painful Bladder Syndrome MedDRA version: 8.0;Level: LLT;Classification code 10008928 | Trade Name: IPD® (suplatast tosilate) Product Name: YM672 (IPD®) Product Code: YM672 INN or Proposed INN: Suplatast tosilate Other descriptive name: IPD® (Japanese tradename) | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Denmark;Germany;Sweden | ||
| 4 | EUCTR2005-003367-23-SE (EUCTR) | 01/02/2006 | 06/12/2005 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis - Not available | Interstitial Cystitis / Painful Bladder Syndrome MedDRA version: 8.0;Level: LLT;Classification code 10008928 | Trade Name: IPD® (suplatast tosilate) Product Name: YM672 (IPD®) Product Code: YM672 INN or Proposed INN: Suplatast tosilate Other descriptive name: IPD® (Japanese tradename) | Astellas Pharma Europe B.V. | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Germany;Sweden |